Israel and the United Arab Emirates will work together to advance medical research.
Sheba Medical Center will collaborate with G42 Healthcare, an Abu Dhabi-based health tech company, on joint research projects and clinical trials across the UAE and Israel.
They will team up to find AI-driven solutions related to stem cell research programs, infrastructure building, and collaborations for advancement in healthcare in cardiology, oncology, gynecology, diabetes, fertility and other areas to shape the future of healthcare across both the countries.
They will also focus on major healthcare investments and introducing cutting-edge innovations in healthcare in the UAE and Israel.
Since the signing of the Abraham Accords in 2020, Sheba has played a key role in driving collaboration with Gulf countries to advance global medicine including a partnership with Bahrain’s largest hospitals on research initiatives and a partnership with the Department of Health in Abu Dhabi for developing improved healthcare services.
Professor Dr. Yitshak Kreiss, Director General of Sheba Medical Center, said: “In line with Sheba Medical Center’s commitment to providing ‘hope without boundaries’, improving care, and supporting its patients in combating even the most complex conditions, we are always on the lookout for impactful collaborations.
“We are excited to partner with G42 Healthcare to accelerate clinical research and enhance patient access to novel treatments and help in improving patient outcomes with an emphasis on creating a better quality of life.”
Ashish Koshy, CEO of G42 Healthcare, said: “G42 Healthcare is committed to inventing a better healthcare every day and continues to push the boundaries of innovation with world leaders in the healthcare domain.
“Our collaboration agreement with Sheba Medical Center is part of this commitment. With Sheba, we look forward to leveraging our state-of-the-art research capabilities and groundbreaking technologies to support scientific and ethical research, conducting clinical trials and reporting, expanding, and ensuring access to innovation in life-changing treatments.”